Tags : Supemtek

Sanofi’s Supemtek (quadrivalent recombinant influenza vaccine) Receives the EC’s Approval

Tuba Khan November 19, 2020

Shots: The approval is based on two P-III studies assessing the safety and efficacy of Supemtek (quadrivalent recombinant influenza vaccine) in 10,000 patients with influenza aged > 18yrs. Supemtek is […]readmore

Biotech Regulatory

Sanofi’s Supemtek Receives CHMP’s Positive Opinion for Approval to Prevent

Tuba Khan September 23, 2020

Shots: The CHMP’s recommendation is based on two P-III studies demonstrating the safety and efficacy of Supemtek (quadrivalent recombinant influenza vaccine) in 10,000+ patients aged ≥18yrs. The company expects EC’s […]readmore

Tags : Supemtek

Sanofi’s Supemtek (quadrivalent recombinant influenza vaccine) Receives the EC’s Approval

Sanofi’s Supemtek Receives CHMP’s Positive Opinion for Approval to Prevent

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : Supemtek

Sanofi’s Supemtek (quadrivalent recombinant influenza vaccine) Receives the EC’s Approval

Sanofi’s Supemtek Receives CHMP’s Positive Opinion for Approval to Prevent

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company